
BharCap Partners Closes Oversubscribed Fund II at $652 Million
GREENWICH, Conn.--(BUSINESS WIRE)-- BharCap Partners, LLC ("BharCap"), a private equity firm focused on the financial services sector, today announced the final closing of its second fund, BharCap Partners Fund II, LP ('Fund II'). Fund II was oversubscribed with $652 million in equity capital commitments, 30% above its $500 million target. BharCap has raised over $1.1 billion of committed equity capital through Fund II and affiliated co-investment vehicles.
'We believe this fundraise demonstrates our differentiated value proposition, the quality and depth of our team and the attractiveness of our sector.'
BharCap is led by founding partners Bharath Srikrishnan, Ethan Wang, Jim Rutherfurd, Kevin Becker and Ryan Gean.
Bharath Srikrishnan, Co-Founder and Managing Partner, said, 'First and foremost, I would like to thank everyone who has supported us on this four-year journey. We created BharCap because we believe entrepreneurs in our sector would benefit from a new firm with a distinctive approach. We are highly entrepreneurial professionals who are sector specialists. We have unique operational and strategic capabilities. Our 'Entrepreneurs Backing Entrepreneurs' mantra resonates with management teams. We believe this fundraise demonstrates our differentiated value proposition, the quality and depth of our team and the attractiveness of our sector. With 27 professionals and operating advisors and substantial dry powder, we are well positioned to identify and support outstanding management teams.'
The fund's closing marks a pivotal moment as BharCap continues to source unique investment opportunities which leverage the firm's longstanding relationships with entrepreneurs.
BharCap's Fund II targets management buyouts in asset-light middle-market financial services companies. Our focused sub-sectors include wealth and asset management, insurance distribution and insurance services, financial technology and tech-enabled financial services, and tax, accounting and advisory services. BharCap focuses on companies with recurring revenue, strong profit margins and high free cash flow conversion that we can scale. We seek to invest alongside management teams to capitalize on powerful long-term growth trends, sub-consolidation opportunities in highly fragmented markets and the impact of technological advancement. Fund II and its LP co-investment vehicles typically invest $50 to $300 million in North American companies with EBITDA of $10 to $50 million.
Ethan Wang, Co-Founder and Partner, said, 'With our entrepreneur-centric approach and deep sector expertise, we provide the tools that financial services companies need to succeed. We have a robust pipeline of proprietary investment opportunities sourced by our proactive, outbound calling effort. We are excited to originate new investment opportunities, drive continued success for our portfolio companies and create significant value for our limited partners and management teams.'
Fund II's investors are a diverse group of limited partners from North America, Europe and Asia, including insurance companies, asset managers, public pension plans, institutional consultants, endowments and foundations, high-net-worth individuals and family offices.
Jim Rutherfurd, Co-Founder, Partner and Head of Investor Relations, said, 'We are grateful for and honored by the support from our limited partners, particularly considering the impact of economic and geopolitical uncertainty on the fundraising environment. Our LP base includes some of the most prominent and well-regarded fund investors. Fund II has significant embedded value, and we are highly focused on extending our track record of outstanding asset light financial services investments.'
Fund II has invested approximately 30% of the Fund in four portfolio companies in the insurance brokerage, insurance services, payment processing and wealth management sectors.
For further inquiries or partnership opportunities, please contact Jim Rutherfurd at jim@bharcap.com.
Rede Partners served as placement agent and Kirkland & Ellis served as fund formation legal counsel to BharCap Fund II.
About BharCap Partners:
BharCap Partners, LLC invests in businesses across the financial services industry including wealth and asset management, insurance distribution and insurance services, financial technology and tech-enabled financial services, and tax, accounting and advisory services. BharCap manages over $2 billion of capital. For more information, please visit https://bharcap.com.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Business Insider
2 hours ago
- Business Insider
'It's always a bit surreal': The co-CEOs of Din Tai Fung told BI what it's like running a dumpling empire as brothers
Albert and Aaron Yang, the two North America CEOs of Din Tai Fung, showed up for our online interview sporting the same combed-back hair, button-down shirts, smiles, and energy. Aaron, 33, said that growing up, they got the question of whether they were twins "almost every day." He's the older one, a year senior to Albert. The duo are the third-generation leaders of the Taiwanese dumpling chain, which started as a humble store in the 1970s and now has over 170 outlets in 13 countries. The two grew up helping in their parents' first Din Tai Fung restaurant in Los Angeles after school. Now, they run operations for the chain's 21 North American outlets. Albert said growing up, their parents never forced them to work in the business, but it felt like a duty to both of them. The two have had parallel and identical career trajectories, starting as restaurant managers in Din Tai Fung's California outlets in 2015. They even went to the same college, Cornell University, to pursue hospitality degrees. They moved up the ladder to become general managers of the chain in California in 2016, US co-vice presidents in 2018, and finally co-CEOs in August 2024. Between launching new stores and doing quality checks on dishes, the brothers spend a lot of time together. "You never really get used to walking into a business meeting and your brother's sitting there," Albert said with a laugh. "It's always a bit surreal." Pairing up makes the job less lonely They said one pro of managing a company with a sibling is that it makes the job feel less isolating. "Being the CEO, or in charge of any company, can be a pretty lonely path. You're sort of alone at the top," Aaron said. "So it's nice to have family you can trust to work together and bounce ideas off each other." A typical day for both men involves leading their corporate team in their LA office or taking flights to different cities in the US and Canada, where they are launching new stores. And like all siblings, the two have their differences. "We really have to work hard to stay on the same page and stay aligned, in the same direction," Aaron said. "It may get contentious from time to time with some minor disagreements," Albert said. But he added that they share the same drive to ensure their family business succeeds. "For the most part, we're very aligned on what we're trying to do. We both understand that we're both very passionate about the business and are just doing everything for the company and our family," Albert added. While they are on the same page about work, there were plenty of ways in which they deviate. Aaron said his favorite meal outside Din Tai Fung was a good In-N-Out burger. "I just love the consistency, quality, and simplicity of a restaurant like In-N-Out. There's a good reason they're like a cult favorite," he said. Albert, who smiles more, said his favorite food was sushi from a family-run restaurant called Sushi Gen in LA. They don't see each other much outside work The two unwind in different ways. Aaron said he likes to golf and get into the woods to connect with nature. Albert is a big sports fan who likes to attend basketball and football games. "We have pretty different personalities and different hobbies. So I'd say we don't really hang out that much outside work, said Aaron. "But it's been kind of like that since growing up." "We went to different high schools, and we're used to having our different friend groups and hobbies. So it wasn't really that big of a change from our childhood," he added. "We don't hang out every day, but it's nice to see Aaron every day at work," Albert said. "We're not the type of brothers who work out every day together or hang out every weekend. But the love and respect are always there."


Business Upturn
4 hours ago
- Business Upturn
Cardiovascular Information System Market to Reach USD 2.8 Billion by 2032, Driven by Digital Health Advancements and Growing Cardiac Care Needs
Austin, June 29, 2025 (GLOBE NEWSWIRE) — Cardiovascular Information System Market Size & Growth Analysis: According to SNS Insider, the Cardiovascular Information System Market was valued at USD 1.24 billion in 2023 and is projected to reach USD 2.8 billion by 2032, growing at a CAGR of 9.4% over the forecast period of 2024–2032. The increasing prevalence of cardiovascular diseases and the need for extensive data management in cardiac care are driving the growth of the global cardiovascular information system market. Emerging technologies including cloud-based solutions, artificial intelligence, and EHR interoperability, are filling clinical workflows. Furthermore, increasing digitization of healthcare, in addition to an improved patient outcomes plan, is anticipated to propel widespread adoption of CVIS across hospitals & specialty care centers. Get a Sample Report of Cardiovascular Information System Market@ The U.S. cardiovascular information system market was estimated at USD 0.33 billion in 2023 and is expected to reach USD 0.73 billion by 2032, at a CAGR of 8.64% during the forecast period of 2024-2032 The North American cardiovascular information system market is dominated by the U.S., attributable to high-end healthcare infrastructure combined with high acceptance of electronic health records and huge investments in digital health technologies. The major CVIS vendors based in this country, coupled with the large number of cardiovascular procedures performed, are continuing to drive the U.S. to a commanding lead in the region. Major Players Analysis Listed in this Report are: Philips Healthcare (IntelliSpace Cardiovascular, Xcelera) Siemens Healthineers (syngo Dynamics, GE Healthcare (Centricity Cardio Enterprise, MUSE Cardiology Information System) McKesson Corporation (McKesson Cardiology, Horizon Cardiology) Agfa Healthcare (IMPAX CV, Enterprise Imaging for Cardiology) Fujifilm Medical Systems (Synapse Cardiovascular, Synapse VNA) LUMEDX Corporation (CardioStar, HealthView CVIS) Cerner Corporation (PowerChart Cardiovascular, CVNet) Merge Healthcare (an IBM Company) (Merge Cardio, Merge Hemo) Digisonics Inc. (DigiView, DigiNet Pro) Cardiovascular Information System Market Report Scope Report Attributes Details Market Size in 2023 US$ 1.24 Billion Market Size by 2032 US$ 2.8 Billion CAGR CAGR of 9.4% From 2024 to 2032 Base Year 2023 Forecast Period 2024-2032 Historical Data 2020-2022 Regional Analysis North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) Segment Analysis: Based on the System, the CVIS Segment Leads the Market In 2023, the cardiovascular information system (CVIS) segment held the highest market share due to the fact that it supports the management, storage, and analysis of cardiovascular data from multiple modalities. By enabling image archiving, real-time access, and clinical EHR integration, CVIS boosts workflow efficiency in cardiac care. Use has also grown, due to the growing need for centralized data management and interoperability within healthcare settings. Web-Based Segment Dominates the Market by Mode of Operation The web-based segment accounted for the largest share in 2023 with a 73% market share, owing to the ease with which this type of system can be deployed, its scalability, and cost-effectiveness. These are essential systems for timely decision-making in cardiovascular care, and their connectivity helps provide real-time access to patient data from various locations. Because they demand little to no infrastructure and integrate easily with existing hospital networks, healthcare providers are increasingly opting for a web-based system. By End User, the Hospitals Segment dominated the Cardiovascular Information System Market The hospital segment accounted for the highest share of the CVIS market in 2023. Due to the high number of cardiovascular procedures carried out in a hospital setting, as well as the healthcare organizations' demand for integrated data management systems. SCV and other partners' healthcare professionals, complex imaging workflows, imaging data, and patient records that hospitals manage require comprehensive solutions such as CVIS. For A Detailed Briefing Session with Our Team of Analysts, Connect with Us Now@ Cardiovascular Information System Market Segmentation By Mode Of Operation Web-based Cloud-based On-site By System By End User Hospitals Large Hospitals Medium-sized Hospitals Small Hospitals Diagnostic Centers Regional Trends: North America to Dominate Cardiovascular Information System Market; Asia-Pacific to Witness Fastest Growth The cardiovascular information system (CVIS) market was dominated by North America in 2023, with 37% market share, owing to the high prevalence of cardiovascular diseases, advanced healthcare infrastructure, and early adoption of health IT systems in this region. From the perspective of the growth factors, major industry presence, solid government support & initiatives for EHR, and large investment in hospitals' digitization were a few that complemented the market growth. The Asia-Pacific region is anticipated to exhibit the fastest growth over the forecast period in the cardiovascular information system market. Some of the major factors driving the growth of the cardiovascular diagnostics market are rapid urbanization, increasing healthcare spending, and increasing awareness of the importance of good cardiovascular health. Table of Contents – Major Key Points 1. Introduction 2. Executive Summary 3. Research Methodology 4. Market Dynamics Impact Analysis 5. Statistical Insights and Trends Reporting 5.1 Adoption Rates of CVIS, 2023 5.2 Device Integration Trends, 2023 5.3 Healthcare Spending on CVIS, by Region, 2023 5.4 Regulatory Compliance and Standardization Trends 5.5 Feature Adoption Trends, 2023 6. Competitive Landscape 7. Cardiovascular Information System Market by Mode Of Operation 8. Cardiovascular Information System Market by System 9. Cardiovascular Information System Market by End User 10. Regional Analysis 11. Company Profiles 12. Use Cases and Best Practices 13. Conclusion Buy a Single-User PDF of Cardiovascular Information System Market Analysis & Outlook Report 2024-2032@ About Us: SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash


Business Wire
5 hours ago
- Business Wire
Aurinia Pharmaceuticals to Host Conference Call to Discuss AUR200 Phase 1 Study Results on June 30, 2025
ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced that it will host a webcast and conference call on June 30, 2025, at 8:30 a.m. ET to discuss AUR200 Phase 1 study results. The link to the webcast is available here. To join the conference call, please dial 877-407-9170/+1 201-493-6756. Click here for participant International Toll-Free access numbers. A replay of the webcast will be available on Aurinia's website. About Aurinia Aurinia is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS ® (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. Aurinia is also developing AUR200, a dual inhibitor of B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for the potential treatment of autoimmune diseases.